Goldman Sachs lowered the firm’s price target on Danaher (DHR) to $240 from $250 and keeps a Neutral rating on the shares after its Q4 earnings miss. The company’s Q1 and FY25 guidance also came in lower than expected, with materially higher China Diagnostic-related VBP headwinds vs. prior guidance, and while its Life Sciences business faces tough one-off comps in Q1, the Biotechnology segment is expected to continue the gradual recovery throughout the upcoming year, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target lowered to $260 from $285 at Jefferies
- DHR Earnings: Danaher Stock Falls 10% on Mixed Financial Results and Weak Guidance
- Morning Movers: Trump Media jumps after announcement of FinTech brand Truth.Fi
- Danaher sees Q1 revenue down low-single digits
- Danaher sees FY25 revenue up 3%